Search results for "Vaccination"
Modeling study finds RSV vaccines cost-effective for older U.S. adults
Vaccination programs using the monovalent adjuvanted or bivalent vaccine against respiratory syncytial virus (RSV) were projected to be potentially cost-effective at a price per dose of up to $127 or up to $118, respectively, over a first RSV season.
https://immattersacp.org/weekly/archives/2023/12/05/4.htm
5 Dec 2023
Raising awareness about HPV-related cancers
The human papillomavirus (HPV) vaccine can potentially prevent more than 90% of HPV-associated cancers. Generally given to teens, it can be offered to adults as well.
https://immattersacp.org/archives/2023/10/raising-awareness-about-hpv-related-cancers.htm
1 Oct 2023
CDC publishes recommendations on use of RSV vaccines
The two vaccines for respiratory syncytial virus (RSV) were approved by the FDA for older adults in May.
https://immattersacp.org/weekly/archives/2023/08/01/4.htm
1 Aug 2023
New findings on antiviral flu treatment
A recent study raises doubts about whether oseltamivir should be promoted as a way to prevent hospitalization in low-risk patients.
https://immattersacp.org/archives/2023/11/new-findings-on-antiviral-flu-treatment.htm
1 Nov 2023
ACIP updates flu vaccination recommendations
The Advisory Committee on Immunization Practices (ACIP) issued its annual update on flu vaccines, including a change in recommendations regarding vaccination of people with egg allergies.
https://immattersacp.org/weekly/archives/2023/08/29/1.htm
29 Aug 2023
The push toward a COVID-19 vaccine
As America closes in on a vaccine for COVID-19, experts focus on which ones will work best, if at all, how to ramp up production, and how to fairly administer millions of doses.
https://immattersacp.org/archives/2020/11/the-push-toward-a-covid-19-vaccine.htm
1 Nov 2020
Coadministration of zoster vaccine, COVID-19 booster appears safe, effective
An industry trial found that coadministration of an mRNA COVID-19 booster vaccine with a first dose of recombinant zoster vaccine was immunologically noninferior to spacing the shots two weeks apart, with a similar safety and reactogenicity profile.
https://immattersacp.org/weekly/archives/2023/06/27/2.htm
27 Jun 2023
More clarity on myocarditis with mRNA COVID-19 vaccines
The classic presentation for COVID-19 vaccine-associated myocarditis is chest pain one to seven days after vaccination, with a median time of three days after vaccination, particularly after the second dose.
https://immattersacp.org/archives/2023/02/more-clarity-on-myocarditis-with-mrna-covid-19-vaccines.htm
1 Feb 2023
New COVID-19 vaccines tested, authorization changes in progress for existing vaccines
The FDA further limited use of the Johnson & Johnson (Janssen) vaccine and scheduled advisory committee meetings on other vaccine questions. Two non-mRNA vaccines showed effectiveness, and other studies looked at antibody prevalence, home test accuracy, and long-term symptoms.
https://immattersacp.org/weekly/archives/2022/05/10/2.htm
10 May 2022
CDC reports on safety after month of COVID-19 vaccines, ACIP updates vaccine schedule
The 2021 schedule from the Advisory Committee on Immunization Practices (ACIP) includes interim recommendations for COVID-19 vaccination, as well as updates for vaccines against influenza, hepatitis A, and others.
https://immattersacp.org/weekly/archives/2021/02/23/3.htm
23 Feb 2021